CEBP CTRC-AACR San Antonio Breast Cancer Symposium 2008 Conference on Cancer Prevention - Washington, D.C.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matusiak, D.
Right arrow Articles by Benya, R. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matusiak, D.
Right arrow Articles by Benya, R. V.
Related Collections
Right arrow Oncogenesis
Right arrow Oncogenesis: Biomarkers
Cancer Epidemiology Biomarkers & Prevention Vol. 14, 2370-2376, October 2005
© 2005 American Association for Cancer Research

Expression of Vitamin D Receptor and 25-Hydroxyvitamin D3-1{alpha}-Hydroxylase in Normal and Malignant Human Colon

Damien Matusiak1,2, Genoveva Murillo3, Robert E. Carroll1,2, Rajendra G. Mehta3 and Richard V. Benya1,2

1 Department of Medicine, University of Illinois at Chicago; 2 Jessie Brown Veterans Administration Medical Center; and 3 Carcinogenesis and Chemoprevention Division, Illinois Institute of Technology Research Institute, Chicago, Illinois

Requests for reprints: Richard V. Benya, Department of Medicine, University of Illinois at Chicago, 840 South Wood Street (M/C 716), Chicago, IL 60612. Phone: 312-569-7439; Fax: 312-569-8114. E-mail: rvbenya{at}uic.edu


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Considerable evidence exists to support the use of vitamin D to prevent and/or treat colorectal cancer. However, the routine use of bioactive vitamin D, 1,25-dihydroxyvitamin D3, is limited by the side effect of toxic hypercalcemia. Recent studies, however, suggest that colonic epithelial cells express 25-hydroxyvitamin D3-1{alpha}-hydroxylase, an enzyme that converts nontoxic pro-vitamin D, 25-hydroxycholecalciferol [25(OH)D3], to its bioactive form. Yet, nothing is known as to the cellular expression of 1{alpha}-hydroxylase and the vitamin D receptor (VDR) in the earliest histopathologic structures associated with malignant transformation such as aberrant crypt foci (ACF) and polyps [addressing the possibility of using nontoxic 25(OH)D3 for chemoprevention], nor is anything known as to the expression of these proteins in colorectal cancer as a function of tumor cell differentiation or metastasis [relevant to using 25(OH)D3 for chemotherapy]. In this study, we show that 1{alpha}-hydroxylase is present at equal high levels in normal colonic epithelium as in ACFs, polyps, and colorectal cancer irrespective of tumor cell differentiation. In contrast, VDR levels were low in normal colonic epithelial cells; were increased in ACFs, polyps, and well-differentiated tumor cells; and then declined as a function of tumor cell de-differentiation. Both 1{alpha}-hydroxylase and VDR levels were negligible in tumor cells metastasizing to regional lymph nodes. Overall, these data support using 25(OH)D3 for colorectal cancer chemoprevention but suggest that pro-vitamin D is less likely to be useful for colorectal cancer chemotherapy.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Vitamin D's ability to prevent colorectal cancer has been suspected for over a quarter of a century. One of the earliest studies supporting this link came from the observation that there was an inverse relationship between mean solar radiation and age-adjusted colorectal cancer death rates (1). Since that time, a number of epidemiologic studies have suggested a link between vitamin D and/or calcium levels and the incidence of human colorectal cancer formation (reviewed in ref. 2). The validity of these epidemiologic observations was significantly enhanced by the results of the Calcium Polyp Prevention Study, a double-blind placebo-controlled study that showed a decreased recurrence rate of colorectal adenomas in patients receiving calcium carbonate (3, 4). Patients receiving the greatest benefit from calcium supplementation were those with decreased serum levels of 25-hydroxycholecalciferol [25(OH)D3; ref. 3], highlighting the importance of vitamin D in inhibiting colorectal cancer formation.

Although vitamin D status in humans is typically assessed by measuring serum 25(OH)D3 levels, this nontoxic pro-vitamin requires hydroxylation at carbon 1 by 25-hydroxyvitamin D3-1{alpha}-hydroxylase to generate bioactive 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]. Whereas the primary function of 1,25(OH)2D3 is to regulate calcium absorption and maintain mineral homeostasis, upon binding to its cognate vitamin D receptor (VDR), 1,25(OH)2D3 also decreases the proliferation and enhances the differentiation of colorectal cancer cells (5) as well as alters the transcription of a large number of genes involved in inhibiting carcinogenesis (6, 7).

Unfortunately, 1,25(OH)2D3 has a narrow therapeutic index, with its propensity for causing toxic hypercalcemia precluding its routine use in otherwise healthy patients. Recently, however, a number of investigators have suggested that 1{alpha}-hydroxylase is present in normal (8, 9) and malignant (10, 11) epithelial cells lining the adult human colon, suggesting that nontoxic 25(OH)D3 might represent an efficacious treatment modality for treating patients with known colorectal polyps or cancer (i.e., chemotherapy), or preventing these lesions from even forming in the first place (i.e., chemoprevention). Yet, the studies done to date have not systematically evaluated VDR and 1{alpha}-hydroxylase expression in colon cancer as a function of tumor cell differentiation or metastasis, critical to assessing 25(OH)D3's potential as a chemotherapeutic agent, nor have they evaluated the expression profile of these proteins in early neoplastic lesions such as aberrant crypt foci (ACF), critical to assessing 25(OH)D3's potential as a chemopreventive agent.

To assess 25(OH)D3's potential for colorectal cancer chemoprevention and/or chemotherapy, we herein report on cellular VDR and 1{alpha}-hydroxylase protein expression in human ACFs, polyps, and colorectal cancer's of defined differentiation along with associated lymph node metastases. To do this, we used quantitative immunohistochemistry to precisely determine VDR and 1{alpha}-hydroxylase expression in formalin-fixed surgically resected tissues at the cellular level. We herein show that 1{alpha}-hydroxylase levels are consistently high in all nonmetastatic tissues, irrespective of histology. In contrast, we show that VDR levels are increased in ACFs and well-differentiated tumors but progressively diminish with colorectal cancer de-differentiation. Lastly, we show that both 1{alpha}-hydroxylase and VDR expression is low to negligible in metastatic tissues, regardless of the histopathologic stage assigned to either the primary tumor or tumor contained within the metastasis. Overall, these findings suggest that 25(OH)D3 has potential for use in colorectal cancer chemoprevention but may be less efficacious for colorectal cancer chemotherapy.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Materials
Anti-VDR antibody was from Abcam (Cambridge, MA). Sheep Anti-murine 25-hydroxyvitamin D3-1{alpha}-hydroxylase antibody was from The Binding Site (San Diego, CA). Goat anti-sheep horseradish peroxidase (HRP)–labeled antibody, goat anti-mouse IgG-HRP, and rabbit anti-goat IgG-HRP was from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). TBST wash buffer, target retrieval solution, protein block serum, antibody diluent, EnVision+ HRP, (DAB)-rabbit system, 3,3'-diaminobenzidine (DAB) chromogen, and automated hematoxylin were all from DAKO (Carpinteria, CA). Auto/iodine, Redusol, and Permount and polyvinylidene difluoride membranes were from Fisher Scientific (Pittsburgh, PA). Mammalian protease inhibitor cocktail was purchased from Sigma (St. Louis, MO). Enhanced Chemiluminescence plus Western Blotting Detection System was from Amersham (Piscataway, NJ); 30% acrylamide/Bis solution and Precision Plus protein standards were from Bio-Rad Laboratories, Inc. (Richmond, CA.); and bicinchoninic acid protein assay kit was from Pierce (Rockford, IL). Calcitriol (1{alpha}, 25-dihydroxyvitamin D3) was purchased from BIOMOL International, LP (Plymouth Meeting, PA).

Tumor Specimens and Histologic Grading
Colon cancers were randomly selected from the University of Illinois at Chicago Gastrointestinal Tumor Bank. The University of Illinois at Chicago and Veterans Administration Institutional Review Boards approved use of these tissues for this study under the stipulation that no linked clinical data could be used as a part of their evaluation and analysis.

Differentiation was assessed as previously described (12-14). Briefly, well-differentiated tumors were defined by the presence of well-formed glands containing malignant columnar cells displaying small regular nuclei. The complete absence of gland formation, or the presence of bizarrely shaped glands, identified poorly differentiated tumors. Moderately differentiated tumors possessed well-formed glands, but the cells were less columnar or frankly cuboidal, with reduced cell polarity and more dysplastic nuclei than those observed in well-differentiated tumors.

Western Analysis
Confluent cells were rinsed in PBS and lysed in radioimmunoprecipitation assay buffer containing a 1:20 dilution of mammalian protease inhibitor cocktail. Protein concentrations were determined using the bicinchoninic acid protein assay kit as described by manufacturer. In all instances, 20 µg of protein were loaded and electrophoresed across a 10% polyacrylamide gel under denaturing and reducing conditions. The resolved proteins were electrophoretically transferred to polyvinylidene difluoride membranes. Membranes were incubated with primary antibody for 2 hours at the following concentrations: VDR, 1:1,750; {alpha}(OH), 1:150; and actin, 1:100 followed by two sequential 10-minute washes with TBST. VDR and actin immunoreactive bands were visualized using a HRP-conjugated goat anti-rabbit IgG, whereas {alpha}(OH) was visualized using a HRP-conjugated rabbit anti-goat IgG and the Enhanced Chemiluminescence Plus detection system.

Quantitative Immunohistochemistry
Tissues were sectioned (4 µm thick) using a Sakura Accu-Cut SRM 200 Rotary Microtome (Torrance, CA) and processed for antigen retrieval in the following manner. Sections were rehydrated in graded alcohol and a running water bath, placed in auto/iodine for 1 minute, rinsed in Tris-buffered saline Tween 20 (TBST) buffer, rinsed twice for 2 minutes in Redusol, and once again in TBST buffer. The slides were then placed in Target Retrieval Solution at 100°C for 20 minutes, allowed to cool to room temperature, and rinsed once again in TBST.

Immunohistochemistry was done on a DAKO Autostainer Universal Staining System using a two-step indirect immunoperoxidase technique. Briefly, tissues were incubated in a 3% H2O2 solution to quench endogenous peroxidase activity, rinsed with TBST, blocked with protein block serum for 30 minutes, and rinsed in TBST. VDR primary antibody was applied (1:1,750, as determined by antibody titration) for 1 hour at room temperature before rinsing with TBST. Next, labeled polymer rabbit HRP was added for 30 minutes, rinsed thoroughly with TBST followed by incubation with DAB+ chromogen for 8 minutes, and then counterstained for 2 minutes with hematoxylin.

1{alpha}-Hydroxylase primary antibody was applied (1:150, as determined by antibody titration) for 45 minutes at room temperature before rinsing with TBST. Next, rabbit anti-sheep HRP-labeled antibody was applied (1:100) for 45 minutes. Slides were rinsed with TBST followed by DAB chromogen incubation for 5 minutes and counterstained for 2 minutes with hematoxylin. All tissues were then dehydrated in graded alcohol and xylene and cover-slipped using Permount. For all specimens, control tissues were processed identically and at the same time, except that they were not exposed to primary antibody. Thus, all differences between the experimental tissue and the control tissue are ultimately due to DAB identification of the relevant protein.

Chromogen abundance was quantified by quantitative immunohistochemistry as previously described (15, 16). Briefly, images were acquired using a Diagnostic Instruments SPOT RT Digital Scanning Camera (Sterling Heights, MI) attached to a Nikon E600 microscope (Stamford, CT), and image files saved in tagged-image file format. The amount of chromogen per pixel was determined by subtracting the mathematical energy (EM) of the control slide (i.e., not exposed to primary antibody) from that in the homologous region of the experimental slide (i.e., exposed to primary antibody). Chromogen quantity (EM) is expressed as energy units per pixels (eu/pix).

Standards and Statistics
In all instances, immunohistochemical quality control was achieved as follows. Because all runs were done using a computer-controlled DAKO Autostainer, conditions were identical at all times. Additionally, a section from a single tumor was included in all runs to control for experimental variability. The amount of chromogen as determined by quantitative immunohistochemistry revealed run-to-run variability of <5%. Data obtained by quantitative immunohistochemistry was evaluated by using the online statistical calculator provided by the College of Saint Benedict/St. John's University (http://www.physics.csbsju.edu/) using the statistical test as identified in the text, with P < 0.05 considered significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Few studies exist examining 1{alpha}-hydroxylase or VDR protein expression in the colon, whereas no studies have systematically evaluated their expression as a function of tumor cell differentiation. To evaluate the expression of these proteins, we used commercially available polyclonal antibodies: the VDR antibody recognizes amino acids 395 to 413 of the human protein, whereas the 1{alpha}-hydroxylase antibody recognizes the murine protein (specific epitope not defined by the manufacturer). To confirm the specificity of these antibodies, we first evaluated them by Western blot analysis against whole protein lysates obtained from NCM460 cells, a nonmalignant human colon epithelial cell line, and Caco-2 and HT-29 cells, human colon cancer cell lines. The antibody for 1{alpha}-hydroxylase identified a single band at ~56 kDa, whereas that for VDR identified a band at ~52 kDa (Fig. 1A). We further confirmed the specificity of the 1{alpha}-hydroxylase antibody, because the specific epitope was not defined by the manufacturer. Because it has been previously shown that 1,25(OH)2D3 suppresses 1{alpha}-hydroxylase expression in Caco-2 cells (8), we assessed the response of these cells to this secosteroid. In all instances, 50,000 cells were plated in defined medium in 12-well plates and cultured under standard conditions for 24 hours. Cells were then cultured for another 48 hours in serum-free medium alone, serum-free medium containing 0.1% ethanol (v/v), or serum-free medium supplemented with 10 nmol/L calcitrol in 0.1% ethanol (v/v). Caco-2 cells alone or exposed to ethanol vehicle showed strong evidence of 1{alpha}-hydroxylase expression by Western analysis, but this band was specifically and significantly down-regulated after exposure to 10 nmol/L 1,25(OH)2D3 for 48 hours (Fig. 1B) thus confirming the specificity of this commercially available antibody.



View larger version (21K):
[in this window]
[in a new window]
  		Figure 1. Western blot analysis showing 1{alpha}-hydroxylase [{alpha}(OH)] and VDR protein expression in human colonic cell lines. A. Protein lysates from malignant cell lines (Caco-2 and HT-29) and a nonmalignant cell line (NCM-460) were used to ensure the specificity of 1{alpha}-hydroxylase and VDR antibodies, with actin expression shown as a control. B. Additional evidence of specificity for the 1{alpha}-hydroxylase antibody as shown by the ability of a 48-hour incubation with calcitrol [but not ethanol (EtOH) vehicle] to down-regulate the appropriate band.

 
We next used these antibodies to evaluate 1{alpha}-hydroxylase or VDR expression in resected human colon cancers. To do this, we randomly selected 10 colorectal cancer from the University of Illinois at Chicago Gastrointestinal Tumor Bank. Tumor blocks selected for evaluation were those that contained the tumor margin thereby allowing us to evaluate 1{alpha}-hydroxylase or VDR protein expression in normal and malignant colonic epithelial cells from the same patient (Figs. 2 and 3). Because colorectal cancer is heterogeneously differentiated (12, 17, 18), we also could assess the expression of these proteins as a function of tumor cell differentiation, again with all evaluation done in the same patient. Overall, the 10 colorectal cancers studied contained 53 separate and distinct regions of well-differentiated tumor, 66 that were moderately differentiated, and 32 that were poorly differentiated.



View larger version (158K):
[in this window]
[in a new window]
  		Figure 2. Expression of 1{alpha}-hydroxylase in human colon cancer and adjacent nonmalignant tissue. Similar nonnuclear levels of 1{alpha}-hydroxylase expression is noted in normal colonic epithelial cells (A) as in well-differentiated tumor cells (B), moderately differentiated tumor cells (C), and poorly differentiated tumor cells (D). Magnification, x40 and x1,000 (inset).

 


View larger version (156K):
[in this window]
[in a new window]
  		Figure 3. Expression of VDR in human colon cancer and adjacent nonmalignant tissue. VDR is expressed at low levels in normal colonic epithelial cells, with the majority of expression in the nucleus (A). In contrast, VDR expression is increased and predominantly cytoplasmic in well-differentiated tumor cells (B). However, with increasing de-differentiation, significantly less VDR expression is appreciated in moderately differentiated tumor cells (C) and in poorly differentiated tumor cells (D). Magnification, x40 and x1,000 (inset).

 
Overall, 1{alpha}-hydroxylase expression seemed consistently strong in normal and malignant colonic epithelial cells, irrespective of tumor cell differentiation (Fig. 2A-D). In contrast, minimal VDR expression was observed in normal colonic epithelial cells, with the expression localized predominantly in the nucleus (Fig. 3A). With malignant transformation, total cellular VDR expression increased markedly in well-differentiated tumors (Fig. 3B) but then decreased with tumor cell de-differentiation (Fig. 3C-D).

To more accurately quantify 1{alpha}-hydroxylase and VDR expression in these tissues, we used our novel technique of quantitative immunohistochemistry (15, 16), which we have shown quantifies chromogen in a manner that accurately reflects the actual amount of protein present (16). Consistent with our empirical observations as reviewed above, the amount of chromogen due to 1{alpha}-hydroxylase was of similar high levels in normal colonic epithelial cells as in well-differentiated and moderately differentiated colorectal cancer (Fig. 4). In contrast, 1{alpha}-hydroxylase levels were significantly decreased in poorly differentiated tumor cells and in metastases to regional lymph nodes (Fig. 4; P < 0.05, ANOVA). We also studied three tubular, three villous, and three tubulovillous adenomas, neoplastic lesions that can progress to colorectal cancer. These adenomas, irrespective of histopathology, all expressed similar levels of 1{alpha}-hydroxylase as observed in normal colonocytes and well-differentiated and moderately differentiated colorectal cancer (Fig. 4). In contrast, VDR expression was ~5-fold higher in polyps and ~12-fold higher in well-differentiated colorectal cancer than in normal colonic epithelial cells (Fig. 4; P < 0.05, ANOVA). However, this elevation decreased in de-differentiated colorectal cancer such that poorly differentiated tumor cells expressed VDR levels similar to what we observed in polyps, an amount that was significantly less than observed in well-differentiated tumor cells (P < 0.05, ANOVA).



View larger version (14K):
[in this window]
[in a new window]
  		Figure 4. Amount of 1{alpha}-hydroxylase ({circ}) and VDR (•) present in normal colonic epithelium, ACF, polyps, colon cancers of defined differentiation, and tumors metastasizing to regional lymph nodes. In all instances, immunohistochemistry was done and chromogen amount quantified as described in Materials and Methods. Points, means; bars, 95% confidence intervals. The amount of 1{alpha}-hydroxylase in lymph nodes is significantly different from the amount present in all other tissues (ANOVA, P < 0.01). The amount of VDR present in ACFs and polyps are similar and significantly different from that expressed by normal colonic epithelial cells, as well as in well-differentiated and moderately differentiated cancers and metastases to lymph nodes (ANOVA, P < 0.01). Abbreviations: NL, normal colonic epithelium; T, tubulovillous, V, villous, TV, tubulovillous; W, well differentiated; M, moderately differentiated; P, poorly differentiated; LN, lymph node.

 
The earliest histopathologic lesion associated with colorectal cancer malignant transformation is the ACF (19, 20). These lesions are not typically seen during routine colonoscopy but can be visualized with high-magnification endoscopes when suitable contrast stains, such as methylene blue, are used (ref. 21; Fig. 5A). Because screening colonoscopy at the University of Illinois at Chicago is routinely done using magnification chromocolonoscopy, our Gastrointestinal Tumor Bank has a large collection of human ACFs for study. We therefore randomly selected five ACF for immunohistochemical evaluation. Whereas 1{alpha}-hydroxylase expression levels were similar to what we observed in normal colonic epithelia and in polyps (Figs. 4 and 5B), the amount of VDR detected was the same as observed in polyps (Figs. 4 and 5C). Overall, then, these data suggest that 1{alpha}-hydroxylase and VDR expression levels in colorectal cancer precursor lesions such as ACFs and polyps may well allow for pro-vitamin D drugs such as 25(OH)D3 to be used for colorectal cancer chemoprevention.



View larger version (94K):
[in this window]
[in a new window]
  		Figure 5. Expression of 1{alpha}-hydroxylase and VDR in a human ACF. A. ACF detected during magnification chromocolonoscopy (arrowhead). B. 1{alpha}-Hydroxylase expression in ACF (boxed region) with surrounding normal epithelium. Magnification, x100. C. VDR expression in ACF (boxed region) with surrounding normal epithelium. Magnification, x100. Insets, greater cellular detail provided. Magnification, x400.

 
Importantly, there has been no significant improvement in the survival of patients with solid tumors that metastasize, including those affecting the colon, since the 1950s (22). Hence, we next studied all resected lymph nodes from additional five patients with known lymph node metastases. Overall, 24 separate lymph nodes (range, 2-9 per patient) were evaluated, of which 12 contained metastatic colorectal cancer. Of these, five contained metastatic tumor deposits that histologically were well differentiated (Fig. 6). We quantified the amount of VDR chromogen in well-differentiated tumor cells contained within the primary cancer and in the five well-differentiated lymph node metastases. High levels of VDR-specific chromogen were detected in well-differentiated tumor cells located within the primary cancer (402 ± 28 eu/pix, mean ± SE), whereas little to no VDR-specific chromogen was detected in well-differentiated tumor deposits metastatic to regional lymph nodes (34 ± 5 eu/pix; P < 0.05, unpaired t test; Fig. 7).



View larger version (74K):
[in this window]
[in a new window]
  		Figure 6. Expression of VDR in primary tumor (left) and associated lymph node metastasis (right). Note that tumor cells in both the primary and metastatic lesion are well differentiated but that VDR can only be detected immunohistochemically in the primary tumor. Tissues were obtained from the University of Illinois at Chicago Gastrointestinal Tumor Bank and processed as described in Materials and Methods.

 


View larger version (29K):
[in this window]
[in a new window]
  		Figure 7. Amount of VDR chromogen present in primary tumors ({circ}) and associated metastases to regional lymph nodes (•). Five tumors with known lymph node metastases were randomly selected from the University of Illinois at Chicago Gastrointestinal Tumor Bank. All surgically resected lymph nodes were evaluated for evidence of tumor infiltration. Lymph nodes containing well-differentiated tumor (n = 5) were processed immunohistochemically for VDR expression at the same time as the primary lesion, and chromogen quantified as described in Materials and Methods. Chromogen quantity for well-differentiated regions within the primary tumors and for the well-differentiated tumor nest within the relevant lymph node (P < 0.05, paired t test). Points, means; bars, ±SE.

 
Because VDR acts by translocating to the nucleus after binding ligand, we used our technique of quantitative immunohistochemistry to assess the relative amounts of VDR expressed in nuclear and nonnuclear (i.e., cytoplasmic) regions (Fig. 8). Intriguingly, the ratio of nuclear to cytoplasmic VDR exceeded 4 in normal colonic epithelial cells, indicating that most of this protein was in the nucleus (Fig. 8, inset; Fig. 3A). However, this ratio dropped to <1.0 for ACFs, the earliest lesion associated with colorectal cancer malignant transformation. This ratio remained between 0.9 and 0.4 for all histopathologic types evaluated except for poorly differentiated colorectal cancer and tumors metastatic to regional lymph nodes (ratio, <0.2; Fig. 8, inset; Fig. 3D). Thus, these data suggests that an ever-declining percentage of VDR translocates, or is able to translocate, to the nucleus of colonic epithelial cells that are not histologically normal. In concert with our observation that 1{alpha}-hydroxylase and VDR are essentially not present in metastatic cells, these data suggest that pro-vitamin D analogues such as 25(OH)D3 may not be efficacious for colorectal cancer chemotherapy.



View larger version (18K):
[in this window]
[in a new window]
  		Figure 8. Nuclear versus cytoplasmic VDR expression in normal colonic epithelium, ACF, polyps, colon cancers of defined differentiation, and tumors metastasizing to regional lymph nodes. In all instances, immunohistochemistry was performed and chromogen quantified as described in Materials and Methods. Columns, means; bars, ±SE. Inset, nuclear to cytoplasmic ratio of VDR expression as determined by quantitative immunohistochemistry. Abbreviations: NL, normal colonic epithelium; T, tubulovillous; V, villous; TV, tubulovillous; W, well differentiated; M, moderately differentiated; P, poorly differentiated; LN, lymph node.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Vitamin D deficiency is well established as a risk factor for colorectal cancer (reviewed in ref. 2). Upon binding to the VDR, 1,25(OH)2D3 decreases the proliferation of a variety of human colon cancer cell lines (23, 24) as well as of cells within resected human rectal mucosa (25). Moreover, VDR-null mice exhibit decreased markers of cellular proliferation and increased levels of markers reflecting DNA oxidative stress (26), suggesting that the vitamin D-receptor complex acts by attenuating oxidative DNA damage and preventing malignant transformation from occurring. Additionally, once malignant transformation has occurred, 1,25(OH)2D3 induces apoptosis (27, 28) as well as has pro-differentiating effects (27) on various colorectal cancer cell lines. Thus, vitamin D may have colorectal cancer chemotherapeutic in addition to chemopreventive effects.

Despite the evidence for increasing hypovitaminosis D in the general population (29-31), widespread use of 1,25(OH)2D3 is not likely to occur given its narrow therapeutic range and side effect profile, even in individuals with known colorectal cancer. However, a role for nontoxic 25(OH)D3 in colorectal cancer chemoprevention and chemotherapy might be reasonable if 1{alpha}-hydroxylase is present, along with the VDR, in relevant locations so as to allow for local generation of bioactive vitamin D. Hence, the purpose of the current study was to systematically assess 1{alpha}-hydroxylase and VDR cellular expression in normal and neoplastic colonic epithelium.

Few studies have systematically evaluated both 1{alpha}-hydroxylase and VDR expression in normal, premalignant, and malignant tissues. It has been suggested that 1{alpha}-hydroxylase expression is higher in colorectal cancer compared with adjacent normal tissues at both the mRNA (11) and protein (32) levels. In contrast, whereas some have reported increased 1{alpha}-hydroxylase expression in well-differentiated colorectal cancer compared with poorly differentiated tumors (33), others have reported the converse (10). We are aware of but two studies looking at both 1{alpha}-hydroxylase and VDR expression in colorectal cancer as a function of tumor differentiation (34, 35). In these, "low-grade" tumors expressed increased amounts of 1{alpha}-hydroxylase and VDR mRNA and/or protein compared with adjacent normal mucosa. These investigators reported that 1{alpha}-hydroxylase and VDR mRNA and/or protein expression then decreased as tumors de-differentiated (34, 35). Yet, these studies evaluated whole tumors and did not study 1{alpha}-hydroxylase/VDR expression at the cellular level.

Clinically, the most important implication of tumor differentiation relates to the fact that it predicts the development of metastases for most solid tumors (36, 37). In contrast, colon cancers are unusual and differ from most other solid tumors, including even rectal cancers (17), insofar they tend to be heterogeneously differentiated (12, 18). Thus, assessing an entire colon cancer's "differentiation," as is usually done by clinical pathologists when assessing tumor "grade," does not provide information useful for predicting a patient's outcome or survival. However, when the differentiation of specific cell populations within a colon cancer is considered, this variable does yield prognostic information (38, 39). For example, individual tumors containing well-differentiated cells at the leading edge (39), or at the point of budding (38), do better even in the face of local lymph node invasion than tumors not associated with local metastases but which are comprised of less well differentiated cells. Thus, differentiation and the factors regulating tumor cell appearance are as important in colon cancer as for other solid tumors, providing that this analysis be done at the level of the individual tumor cell. In this study, we make use of our powerful technique of quantitative immunohistochemistry (15, 16) to show for the first time the degree to which both 1{alpha}-hydroxylase and VDR are expressed at the cellular level in colonic epithelia as a function of histology. Whereas 1{alpha}-hydroxylase is expressed in uniformly high levels in normal and neoplastic colonic epithelial cells, VDR expression is low in normal colonic epithelia, is increased in better differentiated tumor cells, and decreases in poorly differentiated tumor cells, within any particular colorectal cancer. Most importantly, we show that the expression of both 1{alpha}-hydroxylase and VDR is decreased in lymph node metastases, irrespective of the degree to which the tumor cells are differentiated in the metastatic lesion.

Our technique for quantitative immunohistochemistry also permitted us to determine the amount of VDR chromogen present in nuclear and cytoplasmic regions of each cell. In so doing, we could calculate the relative amount present in the nucleus compared with the cytoplasm, a marker of VDR nuclear translocation and thus of "activity." Nuclear-to-cytoplasmic VDR ratios drop dramatically in even ACFs and decline further thereafter in neoplastic lesions as a function of histology. Thus, these findings indicate that, despite uniformly high levels of 1{alpha}-hydroxylase, pro-vitamin D [i.e., 25(OH)D3] may be less likely to be of value for colorectal cancer chemotherapy. Although the significance of this finding is not clear, it is possible, given the observation that VDR polymorphisms can result in nonfunctional protein (40, 41) and that tumor de-differentiation might be associated with increasing mutation of the VDR gene. If so, this would be similar to what has been observed for the gene for the colon cancer morphogen, gastrin-releasing peptide receptor (13).

This study is also the first to evaluate 1{alpha}-hydroxylase and VDR expression in the earliest lesion associated with malignant transformation in the colon, ACF. ACFs were first defined in the colons of rodents exposed to carcinogens and identified soon thereafter in human colons (20). ACFs are associated with adenomatous polyp (42) and colorectal cancer formation in humans (20) and have become an accepted biomarker for assessing the efficacy of chemopreventive drugs in various nonhuman colorectal cancer models (43). Whereas polyps are relatively fixed as lesions, ACF seem fluid and can readily change in number over time (44). Thus, our finding that ACFs, as well as premalignant polyps, express high levels of 1{alpha}-hydroxylase and VDR, suggest that pro-vitamin D may be of value as a chemopreventive agent.

In summary, we herein show that whereas (a) 1{alpha}-hydroxylase is present in uniformly high levels in normal and neoplastic colonic epithelia, except for tumor cells metastatic to regional lymph node; (b) VDR expression is low in normal colonic epithelial cells, increases with malignant transformation and then declines with progressive tumor de-differentiation. Lastly, we show that (c) declining ratios of VDR expression in the nucleus compared with the cytoplasm in neoplastic lesions suggests that less of this protein translocates to the nucleus as tumors progress. Overall, then, these data support using pro-vitamin D analogues in colorectal cancer chemoprevention, whereas they are less likely to be useful for colorectal cancer chemotherapy.


   Footnotes
 
Grant support: Veterans Administration Merit Review (R.E. Carroll and R.V. Benya) and NIH grants CA103861 (G. Murillo), CA82316 (R.G. Mehta), and CA-094346 (R.V. Benya).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 4/13/05; revised 7/13/05; accepted 8/11/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol 1980;9:227–31.[Abstract/Free Full Text]
  2. Harris DM, Go VL. Vitamin D and colon carcinogenesis. J Nutr 2004;134:3463–71S.
  3. Grau MV, Baron JA, Sandler RS, et al. Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst 2003;95:1765–71.[Abstract/Free Full Text]
  4. Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 1999;340:101–7.[Abstract/Free Full Text]
  5. Lin R, White JH. The pleiotropic actions of vitamin D. BioEssays 2004;26:21–8.[CrossRef][Medline]
  6. Freedman LP. Transcriptional targets of the vitamin D3 receptor-mediating cell cycle arrest and differentiation. J Nutr 1999;129:581–6S.[Abstract/Free Full Text]
  7. Tong WM, Kallay E, Hofer H, et al. Growth regulation of human colon cancer cells by epidermal growth factor and 1,25-dihydroxyvitamin D3 is mediated by mutual modulation of receptor expression. Eur J Cancer 1998;34:2119–25.
  8. Cross HS, Kallay E, Khorchide M, Lechner D. Regulation of extrarenal synthesis of 1,25-dihydroxyvitamin D3-relevance for colonic cancer prevention and therapy. Mol Aspects Med 2003;24:459–65.[CrossRef][Medline]
  9. Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin D(3)-1 {alpha}-hydroxylase. J Clin Endocrinol Metab 2001;86:888–94.[Abstract/Free Full Text]
  10. Tangpricha V, Flanagan JN, Whitlatch LW, et al. 25-hydroxyvitamin D-1{alpha}-hydroxylase in normal and malignant colon tissue. Lancet 2001;357:1673–4.[CrossRef][Medline]
  11. Ogunkolade BW, Boucher BJ, Fairclough PD, et al. Expression of 25-hydroxyvitamin D-1-{alpha}-hydroxylase mRNA in individuals with colorectal cancer. Lancet 2002;359:1831–2.[CrossRef][Medline]
  12. Carroll RE, Matkowskyj KA, Chakrabarti S, McDonald TJ, Benya RV. Aberrant expression of gastrin-releasing peptide and its receptor by well differentiated colon cancers in humans. Am J Physiol 1999;276:G655–65.
  13. Glover SC, Tretiakova MS, Carroll RE, Benya RV. Increased frequency of GRPR gene mutations during colon adenocarcinoma progression. Mol Carcinog 2003;37:5–15.[CrossRef][Medline]
  14. Matkowskyj KA, Keller K, Glover S, Kornberg L, Tran-Son-Tay R, Benya RV. Expression of GRP and its receptor in well differentiated colon cancer cells correlates with the presence of focal adhesion kinase phosphorylated at tyrosines 397 and 407. J Histochem Cytochem 2003;51:1041–8.[Abstract/Free Full Text]
  15. Matkowskyj KA, Schonfeld D, Benya RV. Quantitative immunohistochemistry by measuring cumulative signal strength using commercially available software Photoshop and Matlab. J Histochem Cytochem 2000;48:303–11.[Abstract/Free Full Text]
  16. Matkowskyj KA, Cox R, Jensen RT, Benya RV. Quantitative immunohistochemistry by measuring cumulative signal strength accurately measures protein concentration. J Histochem Cytochem 2003;51:205–14.[Abstract/Free Full Text]
  17. Jass JR, Atkin WS, Cuzick J, et al. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology 1986;10:437–59.[Medline]
  18. Steinberg SM, Barwick KW, Stablein DM. Importance of tumor pathology and morphology in patients with surgically resected colon cancer. Cancer 1986;58:1340–5.[CrossRef][Medline]
  19. Bird RP, CK G. The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol Lett 2000;112–113:395–402.[CrossRef]
  20. Takayama T, Katsuki S, Takahashi Y, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998;339:1277–84.[Abstract/Free Full Text]
  21. Carroll RE. Colon preparation for magnification endoscopy: a rapid novel approach. Endoscopy 2004;36:609–11.[Medline]
  22. Leaf C. Cancer's big killers. Fortune 2004 March;22:76–95.
  23. Lointier P, Wargovich MJ, Saez S, Levin B, Wildrick DM, Boman BM. The role of vitamin D3 in the proliferation of a human colon cancer cell line in vitro. Anticancer Res 1987;7:817–21.[Medline]
  24. Shabahang M, Buras RR, Davoodi F, et al. Growth inhibition of HT-29 human colon cancer cells by analogues of 1,25-dihydroxyvitamin D3. Cancer Res 1994;54:4057–64.[Abstract/Free Full Text]
  25. Thomas MG, Tebbutt S, Williamson RC. Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line. Gut 1992;33:1660–3.[Abstract/Free Full Text]
  26. Kallay E, Pietschmann P, Toyokuni S, et al. Characterization of a vitamin D receptor knockout mouse as a model of colorectal hyperproliferation and DNA damage. Carcinogenesis 2001;22:1429–35.[Abstract/Free Full Text]
  27. Vandewalle B, Wattez N, Lefebvre J. Effects of vitamin D3 derivatives on growth, differentiation and apoptosis in tumoral colonic HT 29 cells: possible implication of intracellular calcium. Cancer Lett 1995;97:99–106.[CrossRef][Medline]
  28. Diaz GD, Paraskeva C, Thomas MG, Binderup L, Hague A. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res 2000;60:2304–12.[Abstract/Free Full Text]
  29. Tangpricha V, Pearce EN, Chen TC, Holick MF. Vitamin D insufficiency among free-living healthy young adults. Am J Med 2002;112:659–62.[CrossRef][Medline]
  30. Stokstad E. Nutrition. The vitamin D deficit. Science 2003;302:1886–8.[Abstract/Free Full Text]
  31. Holick MF. Vitamin D requirements for humans of all ages: new increased requirements for women and men 50 years and older. Osteoporos Int 1998;8 Suppl 2:S24–9.
  32. Bareis P, Bises G, Bischof MG, Cross HS, Peterlik M. 25-hydroxy-vitamin D metabolism in human colon cancer cells during tumor progression. Biochem Biophys Res Commun 2001;285:1012–7.[CrossRef][Medline]
  33. Bises G, Kallay E, Weiland T, et al. 25-Hydroxyvitamin D3-1{alpha}-hydroxylase expression in normal and malignant human colon. J Histochem Cytochem 2004;52:985–9.[Abstract/Free Full Text]
  34. Kallay E, Bareis P, Bajna E, et al. Vitamin D receptor activity and prevention of colonic hyperproliferation and oxidative stress. Food Chem Toxicol 2002;40:1191–6.[CrossRef][Medline]
  35. Cross HS, Bareis P, Hofer H, et al. 25-Hydroxyvitamin D(3)-1{alpha}-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 2001;66:287–92.[CrossRef][Medline]
  36. Kowalski LP, Medina JE. Nodal metastases: predictive factors. Otolaryngol Clin North Am 1998;31:621–37.[CrossRef][Medline]
  37. Birchmeier W, Behrens J, Weidner KM, Hulsken J, Birchmeier C. Epithelial differentiation and the control of metastasis in carcinomas. Curr Top Microbiol Immunol 1996;213:117–35.
  38. Hase K, Shatney C, Johnson D, Trollope H, Vierra M. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum 1993;36:627–35.[CrossRef][Medline]
  39. Wood CB, Gillis CR, Hole D, Malcom AJH, Blumgart LH. Local tumor invasion as a prognostic factor in colorectal cancer. Br J Surg 1981;68:326–8.[Medline]
  40. Slattery ML, Neuhausen SL, Hoffman M, et al. Dietary calcium, vitamin D, VDR genotypes and colorectal cancer. Int J Cancer 2004;111:750–6.[CrossRef][Medline]
  41. Mishra DK, Bid HK, Srivastava DS, Mandhani A, Mittal RD. Association of vitamin D receptor gene polymorphism and risk of prostate cancer in India. Urol Int 2005;74:315–8.[Medline]
  42. Yokota T, Sugano K, Kondo H, et al. Detection of aberrant crypt foci by magnifying colonoscopy. Gastrointest Endosc 1997;46:61–5.[CrossRef][Medline]
  43. Hawk ET, Umar A, Viner JL. Colorectal cancer chemoprevention: an overview of the science. Gastroenterology 2004;126:1423–47.[CrossRef][Medline]
  44. Bjerknes M, Cheng H, Hay K, Gallinger S. APC mutation and the crypt cycle in murine and human intestine. Am J Pathol 1997;150:833–9.[Abstract]



This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. Pilz, H. Dobnig, B. Winklhofer-Roob, G. Riedmuller, J. E. Fischer, U. Seelhorst, B. Wellnitz, B. O. Boehm, and W. Marz
Low Serum Levels of 25-Hydroxyvitamin D Predict Fatal Cancer in Patients Referred to Coronary Angiography
Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1228 - 1233.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
D. Matusiak and R. V. Benya
CYP27A1 and CYP24 Expression as a Function of Malignant Transformation in the Colon
J. Histochem. Cytochem., December 1, 2007; 55(12): 1257 - 1264.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
L. Taglia, D. Matusiak, K. A. Matkowskyj, and R. V. Benya
Gastrin-releasing peptide mediates its morphogenic properties in human colon cancer by upregulating intracellular adhesion protein-1 (ICAM-1) via focal adhesion kinase
Am J Physiol Gastrointest Liver Physiol, January 1, 2007; 292(1): G182 - G190.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matusiak, D.
Right arrow Articles by Benya, R. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matusiak, D.
Right arrow Articles by Benya, R. V.
Related Collections
Right arrow Oncogenesis
Right arrow Oncogenesis: Biomarkers

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online